Briefing
Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer.
ctDNA was studied as a recurrence-risk marker in people with resectable gastric and gastroesophageal junction adenocarcinoma receiving perioperative chemotherapy. The abstract does not name the assay.
- Design: Evidence level 3
- Assay: Not named in the abstract